Cocrystal Therapeutics Gets FDA Fast Track FDA granted Fast Track on Apr 2, 2026 for Cocrystal's norovirus antiviral; CDC estimates 19–21M US cases annually and global burden ~685M (Lancet).

Cocrystal Therapeutics Gets FDA Fast Track: FDA granted Fast Track on Apr 2, 2026 for Cocrystal's norovirus antiviral; CDC estimates 19–21M US cases annually and global burden ~685M (Lancet). 👈 Read full analysis #CocrystalTherapeutics #FastTrack #FDAApproval #Norovirus #Antiviral